Retatrutide
Triple incretin receptor agonist (GLP-1 / GIP / Glucagon). Next-generation metabolic research compound.
Select Size
For research use only · 18+ · CoA included with every order
Free Shipping
On orders over £150
Discreet Packaging
Plain, unmarked box
CoA Included
Full lab report
HPLC Tested
Every batch verified
Research Overview
Retatrutide (LY3437943) is a next-generation triple incretin receptor agonist developed for metabolic research. It simultaneously activates GLP-1, GIP, and glucagon receptors, making it one of the most potent compounds studied for obesity and metabolic syndrome research. Phase 2 clinical data has shown substantial weight reduction outcomes.
Key Research Areas
- ›Triple receptor agonist — targets GLP-1, GIP, and glucagon simultaneously
- ›Studied for significant reductions in body weight in clinical research
- ›May improve insulin sensitivity and glucose regulation
- ›Research suggests superior metabolic outcomes vs dual agonists
Storage
Store lyophilised powder at -20°C. Once reconstituted, store at 4°C and use within 28 days. Protect from light.
Specifications
Research Use Only. This product is intended strictly for laboratory and scientific research. Not for human consumption. Must be 18+ to purchase.